CLEO Diagnostics Ltd (AU:COV) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cleo Diagnostics Ltd has begun U.S. clinical trials for its pioneering blood test for ovarian cancer, aiming to secure FDA approval by 2025. The trials involve over 8 recruitment centers and are crucial to validating the test’s effectiveness for early-stage cancer detection. This advancement could revolutionize ovarian cancer diagnosis, where current methods are limited to post-surgery analysis.
For further insights into AU:COV stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue